# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
To gain an edge, this is what you need to know today.
- SEC Filing
Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform.
UBS analyst Curt Woodworth maintains Freeport-McMoRan (NYSE:FCX) with a Neutral and raises the price target from $41 to $54.